Cellid Co., Ltd. Logo

Cellid Co., Ltd.

Develops immunotherapeutic vaccines for cancer and infectious diseases.

299660 | KO

Overview

Corporate Details

ISIN(s):
KR7299660001
LEI:
Country:
South Korea
Address:
서울시 관악구 관악로 1 서울대학교 142동 5층, 서울시

Description

Cellid Co., Ltd. is a research and development biotechnology company focused on immunotherapeutic vaccines. The company's activities are centered on two proprietary technology platforms: CeliVax for anti-cancer immunotherapy and an adenovirus vector platform for infectious disease vaccines. The CeliVax platform is used to develop personalized vaccines that utilize a patient's own B cells and monocytes to target specific cancer antigens. The adenovirus vector platform enables the rapid development of safe, non-replicating viral vector vaccines, with a key application being its COVID-19 vaccine candidate. Cellid's pipeline is built upon these core technologies to address unmet medical needs in oncology and virology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-18 00:00
소송등의제기ㆍ신청(일정금액이상의청구)
Korean 8.3 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 1015.8 KB
2025-08-12 00:00
소송등의판결ㆍ결정(일정금액이상의청구)
Korean 7.0 KB
2025-06-30 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 28.4 KB
2025-06-30 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 25.5 KB
2025-06-30 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 25.5 KB
2025-06-30 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 25.5 KB
2025-06-30 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 27.6 KB
2025-06-30 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 26.2 KB
2025-06-30 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 27.6 KB
2025-06-30 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 26.2 KB
2025-06-30 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-06-30 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-06-30 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-06-30 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.2 KB

Automate Your Workflow. Get a real-time feed of all Cellid Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cellid Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cellid Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.